- Eli Lilly and Company
Mortality Data Presented for Patients Treated with Efient(R)/Effient(R) (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery
Chicago, November 16 (ots/PRNewswire) - New results from an observational substudy from TRITON-TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients...
- 16.11.2010, 16:03:03
- /
- OTE0007
- Eli Lilly and Company
Eight out of 10 People Diagnosed With Heart Disease Consider Their Diagnosis a 'Wake-Up Call'
Barcelona, Spain (ots/PRNewswire) -
- 31.08.2009, 16:37:04
- /
- OTE0012
- Eli Lilly and Company
Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
Tokyo and Indianapolis, November 4 (ots/PRNewswire) -
- 04.11.2007, 14:09:42
- /
- OTE0002
- Eli Lilly and Company
In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
Tokyo and Indianapolis, November 4 (ots/PRNewswire) -
- 04.11.2007, 14:04:41
- /
- OTE0001
- Eli Lilly and Company
Patientenregistrierung in Schlüsselstudie der Phase III zum Vergleich von Prasugrel und Clopidogrel bei Patienten mit akutem Koronarsyndrom abgeschlossen
Tokio und Indianapolis (ots/PRNewswire) -
- 16.01.2007, 13:10:42
- /
- OTS0155 OTW0155
Alle Aussendungen
Alle Anhänge
